General MedicationsINTRAVENOUSGeneric
CABAZITAXEL
CABAZITAXEL
Standard Dose
60MG/6ML (10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview CABAZITAXEL is listed in Drugs@FDA under application 208715 (NDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CABAZITAXEL Form and strength SOLUTION;INTRAVENOUS - 60MG/6ML (10MG/ML) Sponsor SANDOZ Submission history Latest submission status date: 2023-10-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview CABAZITAXEL is listed in Drugs@FDA under application 208715 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CABAZITAXEL Form and strength SOLUTION;INTRAVENOUS - 60MG/6ML (10MG/ML) Sponsor SANDOZ Submission history Latest submission status date: 2023-10-27 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.